JF
DYN icon

Jump Financial’s Dyne Therapeutics DYN Stock Holding History

Jump Financial’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,610
Closed -$192K – 2134
2026
Q1 		$192K Sell
10,610
-24,650
-70% -$425K ﹤0.01% 1677
2025
Q4 		$690K Sell
35,260
-64,624
-65% -$1.22M 0.01% 1148
2025
Q3 		$1.26M Buy
+99,884
New +$1.14M 0.02% 909
2025
Q1 		– Sell
-50,911
Closed -$1.2M – 1689
2024
Q4 		$1.2M Buy
+50,911
New +$1.51M 0.03% 684
2024
Q2 		– Sell
-27,382
Closed -$777K – 1912
2024
Q1 		$777K Buy
+27,382
New +$619K 0.02% 939
2023
Q2 		– Sell
-24,064
Closed -$277K – 1884
2023
Q1 		$277K Sell
24,064
-9,291
-28% -$121K 0.01% 1158
2022
Q4 		$387K Buy
33,355
+3,167
+10% +$36.6K 0.02% 893
2022
Q3 		$383K Buy
+30,188
New +$346K 0.01% 1014
2022
Q1 		– Sell
-19,100
Closed -$227K – 1633
2021
Q4 		$227K Buy
+19,100
New +$268K 0.01% 1047

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jump Financial's DYN Position: Q2 2026 in Review

Jump Financial sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 10,610 shares — an estimated $192K sold.

Jump Financial first reported a position in DYN in Q4 2021 and held it in 9 quarters. The position peaked at $1.26M in Q3 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Jump Financial reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 10,610 Dyne Therapeutics shares in Q2 2026, an estimated $192K.
  • Jump Financial first reported a position in Dyne Therapeutics in Q4 2021 and held it in 9 quarters.
  • Jump Financial's Dyne Therapeutics position peaked at $1.26M in Q3 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.